HC Wainwright maintains Buy rating on Halozyme, $130 target
HC Wainwright & Co. maintained a Buy rating on Halozyme Therapeutics with a $130.00 price target, implying upside versus the Oct 7 close.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.